Cyclacel Pharmaceuticals Q3 EPS $(0.49) Misses $(0.36) Estimate
Portfolio Pulse from mahesh@benzinga.com
Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported a Q3 EPS loss of $(0.49), missing the consensus estimate of $(0.36) by 36.11%. This represents a 16.67% increase in losses compared to the same period last year.
November 13, 2023 | 10:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cyclacel Pharmaceuticals reported a larger than expected quarterly loss, missing analyst estimates, which could lead to negative investor sentiment in the short term.
Earnings misses typically result in negative short-term market reactions as they reflect poorer financial performance than expected. The 36.11% miss is significant and the increase in losses from the previous year further compounds the negative outlook, likely leading to a decrease in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100